САРКОИДОЗ И COVID-19: ОПЫТ ФГБНУ «ЦНИИТ»

Abstract

Our objective was to study the impact of prior sarcoidosis treatment and past COVID-19 on the course of sarcoidosis in patients hospitalized in the Central TB Research Institute. The study enrolled 60 sarcoidosis patients with past COVID-19. We studied case records, clinical manifestations of sarcoidosis and COVID-19, X-ray images, gas exchange function tests. Pulmonary sarcoidosis and sarcoidosis of intrathoracic lymph nodes (ITLN) without involvement of other organs or systems prevailed. The severity of COVID-19 significantly varied, though we did not reveal any correlation between the clinical and radiological patterns of sarcoidosis and the severity of viral lung disease. Exacerbation of sarcoidosis was observed in 27 patients (45%), though without involvement of other organs or systems. We did not detect any significant decrease in diffusing capacity of the lungs or partial pressure of oxygen in arterial blood in sarcoidosis patients after COVID-19. Fifty-two patients (38%) with chronic sarcoidosis continued therapy with systemic glucocorticosteroids (SGCS) during the COVID-19 disease, the stable course of sarcoidosis was observed during one year after COVID-19. The share of patients who did not receive SGCS due to COVID-19 without subsequent exacerbation of sarcoidosis was only 25.64%. The onset of sarcoidosis within one year after COVID-19 was observed in 12 out of 60 patients (20%).